Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin
Drug ID BADD_D01643
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms.[L8648] On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.[T689]
Marketing Status approved; investigational
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00465
MeSH ID C005419
PubChem ID 4634
TTD Drug ID D0R1DH
NDC Product Code 0023-6153; 0023-9637; 70771-1086; 70771-1087; 0615-8220; 50090-5353; 70771-1088; 17381-015; 68382-257; 0615-8219; 68382-255; 68382-256
UNII K9P6MC7092
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H31NO3
CAS Registry Number 5633-20-5
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005--Not Available
Therapeutic response decreased08.06.01.0160.000288%Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.005--
Tinnitus17.04.07.004; 04.04.01.002--
Tongue coated07.14.02.011--Not Available
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urethral pain20.02.02.014--Not Available
Urethritis20.07.02.001; 11.01.14.008--
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.000198%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.000192%
Vision blurred17.17.01.010; 06.02.06.0070.000316%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.0090.000384%Not Available
Bladder spasm20.02.02.0130.000152%
Psychomotor skills impaired19.22.01.002; 17.02.10.005--Not Available
Residual urine volume13.13.03.004--Not Available
Viral diarrhoea11.05.04.012; 07.19.02.008--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Depressive symptom19.15.02.003--Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000192%Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages